NASDAQ · AVR
Healthcare · Medical - Devices
$7.05
Down-$0.50 (-6.62%)
Updated Oct 7, 2026, 3:10 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AVR
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
AVR closed at $7.05 after 21 trading sessions, down 18.21% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $7.57 | $7.655 | $7.02 | $7.05 | 2.64M |
| Oct 5, 2026 | $7.66 | $7.745 | $7.365 | $7.55 | 1.89M |
| Oct 2, 2026 | $7.97 | $8.00 | $7.655 | $7.71 | 1.5M |
| Oct 1, 2026 | $7.74 | $7.86 | $7.52 | $7.61 | 1.17M |
| Sep 30, 2026 | $7.66 | $7.955 | $7.54 | $7.77 | 976.39K |
| Sep 29, 2026 | $7.80 | $7.84 | $7.525 | $7.59 | 782.37K |
| Sep 28, 2026 | $7.63 | $7.755 | $7.555 | $7.74 | 707.19K |
| Sep 25, 2026 | $7.65 | $7.8398 | $7.49 | $7.69 | 762.66K |
| Sep 24, 2026 | $7.60 | $7.6953 | $7.47 | $7.65 | 779K |
| Sep 23, 2026 | $8.03 | $8.035 | $7.57 | $7.62 | 868.78K |
| Sep 22, 2026 | $8.27 | $8.32 | $8.055 | $8.13 | 842.9K |
| Sep 21, 2026 | $8.20 | $8.24 | $7.99 | $8.15 | 744.26K |
| Sep 18, 2026 | $8.40 | $8.57 | $8.12 | $8.16 | 1.81M |
| Sep 17, 2026 | $8.50 | $8.60 | $8.35 | $8.42 | 444.98K |
| Sep 16, 2026 | $8.36 | $8.47 | $8.26 | $8.37 | 968.15K |
| Sep 15, 2026 | $8.68 | $8.71 | $8.30 | $8.34 | 583.67K |
| Sep 14, 2026 | $8.32 | $8.73 | $8.255 | $8.72 | 551.84K |
| Sep 11, 2026 | $8.41 | $8.565 | $8.10 | $8.35 | 640.4K |
| Sep 10, 2026 | $8.35 | $8.45 | $8.2301 | $8.30 | 842.35K |
| Sep 9, 2026 | $8.58 | $8.74 | $8.50 | $8.53 | 681.94K |
| Sep 8, 2026 | $9.04 | $9.04 | $8.61 | $8.62 | 490.55K |
The latest Smart Investors Daily articles mentioning AVR.
Company
Market Activity
Research & News
AVR research
Company profile and research snapshot.
Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Company operates in USA, Germany, Australia, Switzerland, and Sweden. Majority of revenue is from USA.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | Cantor Fitzgerald | Overweight | — |
| May 15, 2026 | Barclays | Overweight | — |
| Mar 27, 2026 | Cantor Fitzgerald | Overweight | — |
| Mar 11, 2026 | Wells Fargo | Overweight | — |
| Jan 8, 2025 | Lake Street | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 6, 2026
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has appointed experienced financial executive Brent Moen as chief financial officer, effective September 12, 2026 AEST. Moen brings more than 25 years of leadership experience across public and private companies, with expertise spanning...
Yahoo · Aug 31, 2026
MINNEAPOLIS and BRISBANE, Australia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson, will be presenting at the Cantor Global Healthcare Conference, the Wells Fargo 21st Annual Healthcare Confere
Benzinga · Aug 14, 2026
Cantor Fitzgerald analyst Gabie Ingoglia reiterates Anteris Technologies Glb (NASDAQ:AVR) with a Overweight and maintains $15 price target.
Benzinga · Aug 12, 2026
Anteris Technologies Glb (NASDAQ:AVR) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.21) by 42.86 percent. This is a 48.28 percent increase over losses of $(0.58) per
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AVR.
